硫普罗宁对原发性肝癌患者血清MMP-9、VEGF及肝功能的影响

Effect of Tiopionin on serum MMP-9 and VEGF levels and liver function of primary liver cancer patients

摘要:

目的探讨硫普罗宁对原发性肝癌血清基质金属蛋白酶-9（MMP-9）、血管内皮生长因子（VEGF）水平和肝功能的影响。方法选取90 例原发性肝癌患者作为研究对象，按照随机数字表法随机分为对照组和观察组各45 例。所有患者均给予化疗栓塞（TACE）治疗。TACE治疗后，对照组患者给予常规治疗，观察组在对照组基础上给予硫普罗宁治疗。比较两组患者近期疗效、肝功能指标和血清MMP-9、VEGF水平。结果治疗后，观察组和对照组患者的近期治疗有效率分别为71.1%和60.0%，组间比较，差异无统计学意义（p >0.05）。观察组患者治疗后谷丙转氨酶（ALT）、谷草转氨酶（AST）、总胆红素（TBIL）、MMP-9 及VEGF 与对照组比较，差异有统计学意义（p <0.05），观察组ALT、AST、TBIL、MMP-9、VEGF比对照组低。结论硫普罗宁可提高原发性肝癌TACE治疗近期有效率，并降低血清MMP-9、VEGF 水平，能够改善患者肝功能，临床上值得进一步研究。

Abstract:

Objective To investigate the effect of Tiopionin on serum levels of matrix metalloproteinase-9(MMP-9) and vascular endothelial growth factor (VEGF), and liver function of primary liver cancer patients.Methods Ninety patients of primary liver cancer meeting the including criteria were selected as research objects. According to random number table, these patients were randomly divided into two groups equally. All patients were treated by TACE. After TACE, the control group was treated with conventional treatment.Besides that, the observation group was treated with Tiopionin. Then, the short-term curative efficacy, liver function indexes and serum levels of MMP -9 and VEGF were compared. Results After treatment, the observation group had a short-term effective rate of 71.1%, which was not statistically different from 60.0% of the control group (p > 0.05). After treatment, the liver function indices including ALT, AST and TBIL in the observation group were statistically lower than those in the control group (p < 0.05). In comparison with control group, the observation group had statistically lower serum levels of MMP-9 and VEGF after treatment (p <0.05). Conclusions Tiopionin improves short-term effective rate and liver function, and reduces serum levels of MMP-9 and VEGF after TACE in patients with primary liver cancer.